[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Florida International University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":534},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,19,0,[8,43,71,99,125,149,173,196,220,254,283,314,336,366,386,414,438,467,489],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100432132","developing-and-testing-health-warning-labels-on-the-ends-device-100432132",false,"NCT04907136","Developing and Testing Health Warning Labels on the ENDS Device","Inclusion Criteria:\n\n* Generally healthy individuals (determined by physical examination).\n* Age of 21-35 years.\n* Is willing to provide informed consent.\n* Is willing to attend the lab as required by the study protocol.\n* ENDS users (defined as using ENDS either daily or occasionally in the past 30 days)\n* Have abstained from ENDS use for 12 hours prior to each session.\n\nExclusion Criteria:\n\n* Report smoking cigarettes regularly (\\> 5 cigarettes\u002Fmonth in the past year).\n* Report regular use of any other tobacco\u002Fnicotine product (e.g., e-cig, pipes, cigars) in the past year.\n* Women who are breast-feeding or test positive for pregnancy (by urinalysis at screening).\n* Individuals with self-reported history of chronic disease or psychiatric conditions.\n* Individuals with history of or active cardiovascular disease, low or high blood pressure, seizures, and regular use of prescription medications (other than vitamins or birth control).\n* Individuals that report the use of non-commercial (i.e., street) e-cigarette liquid or products\n* Individuals that report current EVALI or COVID-19 related symptoms (i.e., cough, shortness of breath, chest pain, nausea, vomiting, abdominal pain, diarrhea, fever, chills, or weight loss)\n* Individuals that have or have been exposed to COVID-19 in the last 14 days.",true,"ALL","21 Years","35 Years",{"count":20,"type":21},80,"ESTIMATED","INTERVENTIONAL",[24],"NA","In this project, after systematically developing electronic nicotine delivery systems (ENDS) pictorial health warning labels (HWLs), a proven clinical lab model will be used to examine and test their effect when these are placed on the ENDS device on a variety of subjective (e.g. satisfaction, harm perception, nicotine dependence, intention to quit) and objective outcomes (e.g. plasma nicotine, puff topography) in young adults.",[27],"Electronic Cigarette Use",[29],"Health Warning Labels","RECRUITING","2026-06-04",{"date":33,"type":34},"2026-06-05","ACTUAL",{"date":36,"type":34},"2023-12-13",{"date":38,"type":21},"2027-04-30",{"name":40,"class":41},"Florida International University","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":18,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":22,"phases":53,"briefSummary":54,"conditions":55,"keywords":57,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":4},"100604929","implementing-who-hearts-d-guidelines-in-bangladesh-for-diabetes-control-and-prevention-100604929","NCT07155902","Implementing WHO HEARTS-D Guidelines in Bangladesh for Diabetes Control and Prevention","Leveraging Community-to-facility Service Provision to Implement the World Health Organization HEARTS-D Guidelines in Bangladesh for Improving Diabetes Control and Prevention (HEARTS-D for Bangladesh)","T2D IR","Inclusion Criteria:\n\n1. Adult individuals, ≥35 years of age,\n2. Of either sex,\n3. Long-term residents in the study area (defined by being a homeowner or a resident for at least the past three years), and\n4. Willing to provide informed consent for study procedures and follow-up.\n\nExclusion Criteria:\n\n1. Individuals planning to migrate from the study area before completing the first 12-month follow-up period, and\n2. Individuals explicitly requesting exclusion from the study or unable to provide consent.",{"count":52,"type":21},5000,[24],"Type-2 diabetes (T2D) is rising at an alarming rate in the low- and middle-income countries (LMIC). This rapid increase in the T2D burden has a particular impact on cities, where more than half the LMIC populations currently live and where 3 out of 4 people with T2D reside. In response to this growing global challenge, the World Health Organization (WHO) has emphasized (a) the need for an equitable and sustained improvement in the detection, treatment, and control of T2D, and (b) a rapid implementation of the WHO's evidence-based HEARTS-D module. However, currently, in most LMICs (such as Bangladesh), effective adoption of the WHO HEARTS-D module into routine urban primary care has been limited. These include suboptimal delivery mechanisms, poor uptake, weak monitoring system, and inadequate capacities. To address this, the investigators will evaluate a community-to-facility integrated strategy to implement WHO HEARTS-D module in the existing urban service delivery system in Bangladesh. First, the investigators will develop and optimize a community-to-facility integrated strategy for adopting the WHO HEARTS-D module using Implementation Mapping. Guided by this approach, the investigators will conduct mixed methods assessments to: (a) identify contextual factors, and (b) assess the implementation behavior of providers that may influence T2D care in cities. The investigators will then develop and optimize a suitable implementation strategy that can achieve high coverage, access and utilization of T2D care, specifically for urban poor populations, through iterative cycles of mixed methods qualitative assessments, implementation, and outcome measurements. For this aim, study staff will select the key stakeholders, primary care providers and CHWs as participants, based in 3 wards in Sylhet city of Bangladesh. Second, the investigators will evaluate the impacts of the optimized community-to-facility integrated strategy on implementation outcomes. The investigators will conduct a 2-arm, type 2, hybrid implementation-effectiveness randomized trial. The study will involve 20 municipal wards as clusters from Sylhet city (10 in each arm). This study compare the following strategies: (a) a community-to-facility integrated strategy for implementing the WHO HEARTS-D module and (b) a facility-only usual service delivery. The investigators will evaluate the implementation process by relevant outcomes based on the RE-AIM framework components: reach, effectiveness, implementation, and maintenance. Third, the investigators will compare the effectiveness of this strategy on T2D status. In a study sample of 10,000 randomly selected participants, the investigators will compare improvements in the prevalence of controlled T2D, treatment uptake and adherence to glucose-lowering therapy, T2D complications and awareness among participants in both study arms from baseline to end-line. Our study should guide the policymakers into effective implementation and sustainment of WHO HEARTS-D module that can be: (a) embedded within local organizational structures, and (b) adapted to similar contexts globally.",[56],"Type 2 Diabetes (T2DM)",[49,58,59,60,61],"HEARTS-D","Type 2 Diabetes","Implementation Research","Non-communicable disease (NCD)","NOT_YET_RECRUITING","2026-05-07",{"date":65,"type":34},"2026-05-08",{"date":67,"type":21},"2026-07",{"date":69,"type":21},"2029-09",{"name":40,"class":41},{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":16,"minAge":79,"maxAge":4,"enrollmentInfo":80,"targetDuration":4,"studyType":22,"phases":82,"briefSummary":83,"conditions":84,"keywords":87,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":42},"100565073","prep-readiness-interventions-for-sustained-motivation-prism-100565073","NCT06637436","PrEP Readiness Interventions for Sustained Motivation (PRISM)","Optimizing HIV Prevention for Highly Vulnerable Methamphetamine-using Sexual Minority Men","PRISM","Inclusion Criteria:\n\n* 18 years or older\n* Assigned male a birth\n* Self-reported methamphetamine use in the past 3 months\n* HIV-negative or unknown serostatus at baseline\n* Has not filled a PrEP prescription in the past 6 months\n\nExclusion Criteria:\n\n* Unwilling or unable to provide informed consent","18 Years",{"count":81,"type":21},400,[24],"This is a hybrid type I randomized controlled trial to test the effectiveness of contingency management (CM) alone versus CM with motivational interviewing (MI) for optimizing entry or re-entry into the HIV prevention or care continua. A total of 400 participants will be randomized to CM (n = 200) or MI+CM (n = 200), all delivered via telehealth. Monthly follow-up assessments will be completed over 12 months to examine effectiveness MI+CM for the primary outcome - filling a pre-exposure prophylaxis (PrEP) or anti-retroviral therapy (ART) prescription (verified using a digital photo). Secondary outcomes will include: self-reported PrEP or ART clinical evaluation by a provider; self-reported meth and other substance use severity (ASSIST), and self-reported receptive and insertive condomless anal sex (CAS).",[85,86],"HIV","Methamphetamine Disorders",[88,89,90,91],"HIV prevention","Methamphetamine","Motivational Interviewing","Contingency Management","2026-05-05",{"date":63,"type":34},{"date":95,"type":34},"2025-01-28",{"date":97,"type":21},"2028-04-30",{"name":40,"class":41},{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":103,"acronym":4,"eligibilityCriteria":104,"healthyVolunteers":11,"sex":16,"minAge":105,"maxAge":4,"enrollmentInfo":106,"targetDuration":4,"studyType":22,"phases":108,"briefSummary":109,"conditions":110,"keywords":113,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":42},"100635366","a-digital-health-parent-training-intervention-for-children-with-social-communication-delays-100635366","NCT07551752","A Digital Health Parent-Training Intervention for Children With Social Communication Delays","Inclusion Criteria:\n\n* Children:\n* aged 14 - 48 months\n* screen positive on the M-CHAT-R\u002FF or already have a diagnosis of autism\n* Parents:\n* Fluent in English\n* Agree to complete both study visits and review OPT-In-Early if randomized to the intervention group\n* At least 18 years old\n* Have access to an internet-connected device\n\nExclusion Criteria:\n\n* Children:\n* Have a neurological condition that would preclude engagement in the intervention or testing","14 Months",{"count":107,"type":21},100,[24],"Early intervention, during a time of optimal brain plasticity, is critical for autistic children to develop functional skills such as communication and daily living abilities. However, many families face barriers to accessing timely autism-specific services due to delays in autism diagnosis (which is often a prerequisite to autism-specific intervention), long waitlists, high costs, and the necessity to travel far distances to service providers. Self-directed parent-mediated digital health interventions (i.e., programs that parents complete online without provider coaching or feedback) offer a scalable solution to reduce challenges accessing intervention by providing evidence-based strategies that parents can implement without relying on traditional service pathways. The proposed pilot randomized controlled trial (RCT) will test a revised self-directed parent-training program, that teaches parents naturalistic developmental behavioral intervention (NDBI) strategies, which have proven effective for young children with autism. The study will include young children who have already been diagnosed with autism and those who screen positive on an autism screener but have not yet been evaluated, enabling earlier intervention before a formal diagnosis. The study will also explore parents' willingness to engage in the intervention. The specific research aims are: (1) test the preliminary efficacy of the parent-training program vs. treatment as usual (TAU) for 50 children with autism traits and their parents; (2) examine parent engagement in the intervention; and (3) explore predictors of engagement.",[111,112],"Autism Spectrum Disorder","Social Communication Delay",[114,115,111,112,116],"Early intervention","Naturalistic Developmental Behavioral Intervention","parent training","2026-04-20",{"date":119,"type":34},"2026-04-27",{"date":121,"type":34},"2026-04-11",{"date":123,"type":21},"2027-05",{"name":40,"class":41},{"id":126,"slug":127,"hasResults":11,"nctId":128,"briefTitle":129,"officialTitle":130,"acronym":4,"eligibilityCriteria":131,"healthyVolunteers":11,"sex":16,"minAge":132,"maxAge":4,"enrollmentInfo":133,"targetDuration":4,"studyType":22,"phases":135,"briefSummary":136,"conditions":137,"keywords":140,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":144,"completionDateStruct":146,"leadSponsor":148,"locationsCount":42},"100634425","a-toolkit-to-improve-mental-health-treatment-for-autistic-individuals-100634425","NCT07539519","A Toolkit to Improve Mental Health Treatment for Autistic Individuals","A Transdiagnostic Toolkit to Improve Mental Health Treatment for Autistic Individuals","The following describes Phase II (the clinical trial):\n\nInclusion Criteria for clients:\n\n* A confirmed diagnosis of autism\n* Between 13 and 17 years old\n* Fluent in English\n* Have a co-occurring mental health condition that is appropriate for treatment at the community clinic participating in the proposed study\n\nExclusion criteria:\n\nN\u002FA\n\nAll therapists working at the community clinic at which this study takes place will be eligible to participate.","13 Years",{"count":134,"type":21},18,[24],"This pilot study is funded by the Organization for Autism Research (OAR). We are conducting a pilot study to improve mental health treatment for autistic individuals. First, we will conduct remote focus groups to identify barriers to mental health treatment and methods to improve treatment. Based on results, we will develop a prototype of a resource for therapists. This resource will be pilot tested in a community clinic.",[138,139],"Autism","Mental Health Conditions",[141],"mental health treatment","2026-04-13",{"date":117,"type":34},{"date":145,"type":21},"2026-04",{"date":147,"type":21},"2027-12",{"name":40,"class":41},{"id":150,"slug":151,"hasResults":11,"nctId":152,"briefTitle":153,"officialTitle":153,"acronym":4,"eligibilityCriteria":154,"healthyVolunteers":11,"sex":16,"minAge":155,"maxAge":156,"enrollmentInfo":157,"targetDuration":4,"studyType":22,"phases":159,"briefSummary":160,"conditions":161,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":166,"startDateStruct":168,"completionDateStruct":170,"leadSponsor":172,"locationsCount":42},"100633466","emerging-technologies-and-teen-mental-health-100633466","NCT07527052","Emerging Technologies and Teen Mental Health","Inclusion Criteria:\n\n* Adolescents must (A) be between ages 12 and 17 years\n* (B) have a positive screen for suicide risk (i.e. endorsement of suicidal ideation via self-report or parent-report)\n* (C) have access to a personal social media account\n* (D) be fluent in English\n* (E) have available a parent who is fluent in English or Spanish.\n\nExclusion Criteria:\n\n* Adolescents must not (A) have cognitive impairment or developmental delay which does not allow for the completion of basic study procedures (i.e., reading and filling out questionnaires; talking to a clinician)\n* (B) show imminent risk or a history of hurting themselves or others requiring intensive and restrictive services.","12 Years","17 Years",{"count":158,"type":21},200,[24],"This study will recruit teens who are experiencing subacute suicidal ideation to test the effect of a brief psychoeducational intervention focused on social media use wherein youth learn about active and prosocial use of social media platforms.",[162,163,164],"Social Functioning","Emotional Distress","Suicidal Ideation","2026-04-08",{"date":167,"type":34},"2026-04-14",{"date":169,"type":34},"2026-03-20",{"date":171,"type":21},"2028-12",{"name":40,"class":41},{"id":174,"slug":175,"hasResults":11,"nctId":176,"briefTitle":177,"officialTitle":178,"acronym":4,"eligibilityCriteria":179,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":180,"targetDuration":4,"studyType":22,"phases":182,"briefSummary":183,"conditions":184,"keywords":185,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":188,"lastUpdatePostDateStruct":189,"startDateStruct":191,"completionDateStruct":193,"leadSponsor":195,"locationsCount":42},"100465291","effect-of-menthol-on-ends-users-addiction-and-exposure-100465291","NCT05338801","Effect of Menthol on ENDS Users' Addiction and Exposure","The Effect of Menthol on ENDS Users' Dependence, Respiratory, and Toxicants Emission Outcomes.","Inclusion Criteria:\n\n* Generally healthy individuals (determined by physical examination).\n* Age of 21-35 years.\n* Is willing to provide informed consent.\n* Is willing to attend the lab as required by the study protocol.\n* E-cigarette users (defined as using e-cigarette either daily or occasionally in the past 30 days)\n* Have abstained from e-cigarette use for 12 hours prior to each session\n\nExclusion Criteria:\n\n* Report smoking cigarettes regularly (\\> 5 cigarettes\u002Fmonth in the past year).\n* Report regular use of any other tobacco\u002Fnicotine product (e.g., e-cig, pipes, cigars) in the past year.\n* Women who are breast-feeding or test positive for pregnancy (by urinalysis at screening).\n* Individuals with self-reported history of chronic disease or psychiatric conditions.\n* Individuals with history of or active cardiovascular disease, low or high blood pressure, seizures, and regular use of prescription medications (other than vitamins or birth control).\n* Individuals that report current THC (marijuana) smoking\u002Fvaping.\n* Individuals that report current EVALI or COVID-19 related symptoms (i.e., cough, shortness of breath, chest pain, nausea, vomiting, abdominal pain, diarrhea, fever, chills, or weight loss)\n* Individuals that have or have been exposed to COVID-19 in the last 14 days.",{"count":181,"type":21},250,[24],"The use of electronic nicotine delivery systems (ENDS; e-cigarettes) has reached epidemic levels among young people in the United States (US). ENDS heat and vaporize a nicotine-containing liquid to produce an inhalable aerosol mist. While generally considered less harmful than combustible cigarettes, ENDS use exposes users to dependence-producing nicotine and respiratory and cardiovascular toxicants such as aldehydes. Flavor is a major factor in getting young people to use ENDS, thus limiting flavors to menthol and tobacco for prefilled cartridge ENDS \"pod mods\" was the first major action taken by the FDA to reduce the spread of ENDS among young people. Menthol flavor, however, can present a potential risk given its increasing popularity among young people in the US, and its puffing and nicotine-enhancing properties. Yet, the extent of menthol's ability to affect users' experience and puffing patterns, and how these affect dependence, exposure to toxicants, and clinical outcomes continue to be understudied. Such evidence will be critical to the FDA's ability to set further regulatory standards to reduce ENDS potential harm. The investigators will conduct a 2x2 (pre-post x menthol vs. tobacco flavor) crossover clinical lab study. The investigator will recruit current\u002Fpast month ENDS users (n=250, 21-35 yrs), who will attend two sessions and use their ENDS once with menthol and once with tobacco flavors. The proposed studies will answer two key regulatory questions consistent with FDA's focus on the role of flavor in tobacco products' addiction and toxicity; 1) compared to tobacco flavor, does menthol carry additional risk by enhancing puffing, abuse liability, and toxicant exposure in ENDS users, and; 2) is this effect more pronounced among high dependence compared to other users. Other outcomes such as harm perception, satisfaction, clinical responses, intention to use or quit, and group comparisons such as according to race, and sex will allow the FDA a comprehensive assessment of the pros and cons of regulating mentholated ENDS for different segments of the society. Such evidence will help advance FDA regulatory policies with the potential to reduce ENDS harm.",[27],[186,187],"Menthol Flavor","Tobacco Flavor","2026-03-31",{"date":190,"type":34},"2026-04-01",{"date":192,"type":34},"2022-06-22",{"date":194,"type":21},"2027-03-31",{"name":40,"class":41},{"id":197,"slug":198,"hasResults":11,"nctId":199,"briefTitle":200,"officialTitle":201,"acronym":202,"eligibilityCriteria":203,"healthyVolunteers":15,"sex":16,"minAge":79,"maxAge":204,"enrollmentInfo":205,"targetDuration":4,"studyType":22,"phases":207,"briefSummary":208,"conditions":209,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":212,"lastUpdatePostDateStruct":213,"startDateStruct":215,"completionDateStruct":217,"leadSponsor":219,"locationsCount":42},"100628948","synchronization-of-theta-to-influence-memory-100628948","NCT07468279","Synchronization of Theta to Influence Memory","Effects of Non-Invasive Brain Stimulation on Task Performance","STIM","Inclusion Criteria:\n\n* 18 years and older\n* Fluent in English\n* Normal or corrected-to-normal vision\n* Willing to be photographed\n\nExclusion Criteria:\n\n* Must not have ever had an injury to the head that's caused you to be knocked out for a period of time (e.g., from a fall, blow to the head, road traffic accident).\n* Must not have an uncorrected vision or physical disability that interferes with your ability to see stimuli presented briefly on a computer screen or click a mouse button rapidly.\n* Must not have a history of epilepsy, convulsions, or seizures (except childhood febrile seizures).\n* Must not have a history of fainting or syncope.\n* For female participants, they must not be pregnant and\u002For must not think they might be pregnant.\n* Must not have skin problems like eczema, dermatitis, or open wounds on the scalp.\n* Must not have had prior brain surgery.\n* Must not have any metal located in the head\u002Fneck (except for dental fillings).\n* Must not have any devices or other implants located in\u002Fnear their head. This includes cochlear implants and aneurysm clips, cardiac pacemaker, or any other implanted electronic device.\n* Must not have a current (active) alcohol or substance use disorder, must have no recent history of withdrawal symptoms, and must be able to safely abstain from alcohol and non-prescribed\u002Fillicit drugs for at least 24 hours before the session.\n* Must not have any alcohol on the day of the session, must limit alcohol consumption to no more than 2 drinks (if legally permitted) in the prior 24 hours, and must not use any non-prescribed or illicit drugs in the 24 hours before the session.\n* Must not be sick with a fever, sleep-deprived, or feel dizzy, unwell, or intoxicated.\n* Must also have eaten and had fluids but not have consumed more caffeine than they typically consume.\n* Must not be taking anticonvulsant\u002Fanti-epileptic drugs or have ever taken them within their lifetime.\n* Must not be taking benzodiazepines or have taken them within the past 3 months.\n* Must not have had a recent change (start, stop, dose change) for any psychiatric\u002Fpsychotropic medications within the past 3 months.\n* Must not be taking Bupropion (Wellbutrin, Zyban), Tricyclic antidepressants (e.g., amitriptyline, imipramine, clomipramine, etc.), Antipsychotics (clozapine; chlorpromazine, haloperidol, etc.), or Tramadol or have taken them within the past 3 months.\n* Must not have experienced cardiac problems, fibrillation, or have taken medications associated with cardiac conditions within the past 3 months.\n* Must not meet the diagnostic threshold for Autism Spectrum Disorder, Intellectual Disability, or Psychotic Disorders.","59 Years",{"count":206,"type":21},90,[24],"This study aims to clarify relations between brain oscillations and two cognitive functions: cognitive control and memory.",[210,211],"Cognitive Control","Memory","2026-03-16",{"date":214,"type":34},"2026-03-17",{"date":216,"type":34},"2026-03-13",{"date":218,"type":21},"2031-01",{"name":40,"class":41},{"id":221,"slug":222,"hasResults":11,"nctId":223,"briefTitle":224,"officialTitle":225,"acronym":226,"eligibilityCriteria":227,"healthyVolunteers":15,"sex":16,"minAge":79,"maxAge":228,"enrollmentInfo":229,"targetDuration":4,"studyType":22,"phases":231,"briefSummary":232,"conditions":233,"keywords":237,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":246,"lastUpdatePostDateStruct":247,"startDateStruct":249,"completionDateStruct":251,"leadSponsor":253,"locationsCount":42},"100607710","a-reinforced-mindfulness-based-intervention-to-reduce-problematic-drinking-among-hispanic-emerging-adults-100607710","NCT07192094","A Reinforced Mindfulness-Based Intervention to Reduce Problematic Drinking Among Hispanic Emerging Adults","A Reinforced Mindfulness-Based Intervention to Reduce Problematic Drinking Among Hispanic Emerging Adults: Feasibility and Acceptability","Mindfulness","Inclusion Criteria:\n\n* self-identified Hispanic,\n* 18-25 years old,\n* engaged in 2 or more occasions of heavy episodic drinking occasions (HED) (4\u002F5 drinks in one sitting for females\u002Fmales) during the previous 30-days\n* actively enrolled FIU student. Exclusion Criteria\n\nParticipants will be flagged for exclusion criteria if they report any of the following:\n\n* Five or more binge drinking episodes (5+ drinks in one sitting) in the past 30 days, which averages more than once per week.\n* Weekly or more frequent use of other substances, including non-prescribed prescription drugs, illegal drugs, inhalants, or synthetic drugs.","25 Years",{"count":230,"type":21},120,[24],"This study is a trial to evaluate a mindfulness program designed for Hispanic young adults. Participants will be randomly assigned to one of two groups: (1) an in-person, 8-week mindfulness program (one 1.5-hour session per week at FIU's MMC campus), or (2) an assessment-only control group. Regardless of group assignment. Participants will be asked to complete online surveys at baseline, after an 8-week period, and again one month later. They will also be asked to provide a fingerpick blood sample and have their heart rate and blood pressure measured at four timepoints: baseline, 1 month, 2 months, and 3 months after baseline. Participation will involve up to 16 hours over approximately 14 weeks. This includes time for completing baseline assessments, participating in the 8-week intervention (if assigned), and completing post-program and follow-up assessments. There are no serious risks of participating in this study, but some of the questions during the assessments, interview, or the fingerpick may cause you discomfort. The main benefit from participating in this clinical trial is that participants may experience personal benefits from learning mindfulness techniques.",[234,235,236],"MBSR","Young Adults","Heavy Episodic Drinking",[238,239,240,241,242,226,243,244,91,234,245],"Young adults","College Students","Ages 18 - 25","Binge Drinking","Stress","Stress Reduction","HRV","alcohol misuse","2026-02-24",{"date":248,"type":34},"2026-02-25",{"date":250,"type":34},"2026-01-27",{"date":252,"type":21},"2028-07",{"name":40,"class":41},{"id":255,"slug":256,"hasResults":11,"nctId":257,"briefTitle":258,"officialTitle":258,"acronym":259,"eligibilityCriteria":260,"healthyVolunteers":11,"sex":16,"minAge":79,"maxAge":4,"enrollmentInfo":261,"targetDuration":4,"studyType":22,"phases":263,"briefSummary":264,"conditions":265,"keywords":269,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":274,"lastUpdatePostDateStruct":275,"startDateStruct":277,"completionDateStruct":279,"leadSponsor":281,"locationsCount":282},"100449762","treatment-research-investigating-depression-effects-on-neuroimmune-targets-trident-100449762","NCT05136703","Treatment Research Investigating Depression Effects on Neuroimmune Targets (TRIDENT)","TRIDENT","Inclusion Criteria:\n\n1. Age 18 or older\n2. Speaks and reads English\n3. Verified HIV+ status with antiretroviral medications bearing his\u002Fher name\n4. Current diagnosis on Major Depressive Disorder (MDD) using a structured clinical interview (DIAMOND) or Hamilton Rating Scale for Depression scores of 7 or greater\n5. If prescribed antidepressants, on a stable regimen and dose for at least 2 months\n6. Suppressed HIV viral load (\\\u003C 200 copies\u002FmL)\n7. Able to complete Functional Magnetic Resonance Imaging (fMRI) scans (i.e., no claustrophobia, no metal implants, no pacemaker, and BMI \\\u003C 40)\n\nExclusion Criteria:\n\n1. Unable to provide informed consent\n2. Active, untreated major mental illness\n3. Pregnancy at baseline\n4. Received CBT for depression in the past 2 years\n5. 5\\. Otherwise eligible but does not complete the run-in period that includes the baseline assessment, biospecimen collection, the fMRI visit, and a separately scheduled randomization visit",{"count":262,"type":21},150,[24],"The purpose of this randomized controlled trial is to understand how a cognitive-behavioral treatment (a form of psychological treatment) for depression changes the gut microbiome (micro-organisms that regulate the health of the gut), immune system, and the brain functioning in people living with HIV.",[266,267,268],"Depression","HIV-1-infection","Inflammation",[266,270,85,271,272,273],"Microbiome","CBT-AD","Gut","Brain","2026-02-04",{"date":276,"type":34},"2026-02-06",{"date":278,"type":34},"2022-08-30",{"date":280,"type":21},"2027-12-31",{"name":40,"class":41},2,{"id":284,"slug":285,"hasResults":11,"nctId":286,"briefTitle":287,"officialTitle":287,"acronym":288,"eligibilityCriteria":289,"healthyVolunteers":11,"sex":290,"minAge":79,"maxAge":4,"enrollmentInfo":291,"targetDuration":4,"studyType":22,"phases":292,"briefSummary":293,"conditions":294,"keywords":296,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":307,"lastUpdatePostDateStruct":308,"startDateStruct":310,"completionDateStruct":312,"leadSponsor":313,"locationsCount":42},"100544918","efficacy-of-mhealth--e-navigator-stepped-care-intervention-for-art-adherence-among-latino-men-with-hiv-100544918","NCT06375135","Efficacy of mHealth + e-Navigator Stepped Care Intervention for ART Adherence Among Latino Men With HIV","Project STEP","1. Latino or Hispanic\n2. Self-report male sex\n3. Age 18 or older\n4. Diagnosed with HIV and prescribed ART least 1 month prior to study screening and enrollment\n5. Suboptimal adherence defined as (1) laboratory evidence of at least one detectable viral load in the past 12 months (≥20 copies\u002FmL), (2) electronic medical record of at least one \\\u003C90% 30-day adherence period in the past 12 months, or (3) self-reported \\\u003C90% past 30-day adherence.\n6. Cell phone ownership and SMS use: Participants must own a personal cell phone for the intervention.","MALE",{"count":181,"type":21},[24],"The goal of this study is to evaluate the efficacy of stepped care strategies to improve ART adherence among adult Latino men with HIV using a sequential, multiple assignment, randomized trial (SMART). The trial will compare a stepped care strategy of delivering TXTXT (\"Treatment Text\") first and stepping up to remote patient navigation for non-responders vs. a stepped care strategy of delivering TXTXT + e-Navigation first and stepping up to EMA-supported e-Navigation for non-responders. Both TXTXT and the foundations of the e-Navigation interventions are CDC evidence-based interventions (EBI). We propose to use a SMART design which explicitly allows building, testing, and optimizing stepped care strategies without compromising rigor or randomization. We propose three specific aims:\n\nAim 1. Compare the immediate (6-month) and sustained (9- and 12-month) efficacy of two static (non-stepped) treatment regimens (TXTXT alone vs. TXTXT + e-Navigation) on ART adherence and viral suppression among Latino men with HIV. Hypothesis 1a. TXTXT + e-Navigation will be more efficacious than TXTXT alone. Aim 2. Compare the immediate (6-month) and sustained (9- and 12-month) efficacy of two stepped care strategies (TXTXT with added e-Navigation for non-responders vs. TXTXT + e-Navigation with added EMA support for non-responders) on ART adherence and viral suppression among Latino men with HIV. Hypothesis 2a: TXTXT + e-Navigation with added EMA support for non-responders at the 3-month follow-up will be more efficacious than TXTXT with added e-Navigation for non-responders at the 3-month follow-up. Aim 3. Identify baseline and time-varying moderators on the association between stepped care strategy and ART adherence and viral suppression among Latino men with HIV. Hypotheses 3a-c: TXTXT with added e-Navigation for non-responders will be less efficacious than TXTXT + e-Navigation with added EMA support for non-responders for individuals who are: (a) older at baseline, or report (b) substance use, or (c) symptoms of depression between baseline and the 3-month follow-up.",[295],"ART Adherence",[297,298,299,300,301,302,303,304,305,306],"HIV\u002FAIDS","Treatment text","Ecological Momentary Assessment","Antiretroviral therapy adherence","medication adherence","viral suppression","HIV care strategies","Latino","Hispanic","SMART design","2026-01-28",{"date":309,"type":34},"2026-01-30",{"date":311,"type":34},"2024-06-06",{"date":194,"type":21},{"name":40,"class":41},{"id":315,"slug":316,"hasResults":11,"nctId":317,"briefTitle":318,"officialTitle":318,"acronym":4,"eligibilityCriteria":319,"healthyVolunteers":11,"sex":16,"minAge":79,"maxAge":4,"enrollmentInfo":320,"targetDuration":4,"studyType":22,"phases":322,"briefSummary":323,"conditions":324,"keywords":326,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":328,"lastUpdatePostDateStruct":329,"startDateStruct":331,"completionDateStruct":333,"leadSponsor":335,"locationsCount":42},"100512039","intervening-with-haitian-immigrants-in-the-us-to-improve-hiv-outcomes-100512039","NCT05947266","Intervening With Haitian Immigrants in the U.S. to Improve HIV Outcomes","Inclusion Criteria:\n\n1. Seropositive for HIV\n2. Either a recent HIV diagnosis (within the last 2 months) or non-virally suppressed.\n3. Migrated to the US from Haiti\n\nExclusion Criteria:\n\n1\\. Virally suppressed",{"count":321,"type":21},66,[24],"The goal of this clinical trial is to test a culturally tailored engagement and retention intervention for Haitian Immigrants Living With HIV (HILWH). The main questions it aims to answer are:\n\n* Does this intervention result in measurable engagement and retention in care?\n* Does this intervention result in measurable viral suppression within 6 months?\n\nParticipants will\n\n* participate in a pilot health intervention entailing 4 individual meetings, approximately once monthly over a six-month period and completing research questionnaires at enrollment, post-intervention and at 6 months post-enrollment.\n* Six participants who have completed the pilot intervention and agree to take part, will participate in the photovoice portion of the study. This activity will consist of 6 additional meetings where participants will be taught about using photographs to illustrate their experience participating in the study and take and display photographs.",[325],"HIV Infection Primary",[327],"Viral suppression","2026-01-21",{"date":330,"type":34},"2026-01-22",{"date":332,"type":34},"2024-06-03",{"date":334,"type":21},"2026-06-30",{"name":40,"class":41},{"id":337,"slug":338,"hasResults":11,"nctId":339,"briefTitle":340,"officialTitle":341,"acronym":342,"eligibilityCriteria":343,"healthyVolunteers":11,"sex":16,"minAge":79,"maxAge":4,"enrollmentInfo":344,"targetDuration":4,"studyType":22,"phases":345,"briefSummary":346,"conditions":347,"keywords":351,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":359,"lastUpdatePostDateStruct":360,"startDateStruct":362,"completionDateStruct":364,"leadSponsor":365,"locationsCount":42},"100590307","use-of-point-of-care-ultrasound-pocus-to-reduce-hospital-length-of-stay-in-patients-with-heart-failure--pocushf--100590307","NCT06965712","Use of Point-of-Care Ultrasound (POCUS) to Reduce Hospital Length of Stay in Patients With Heart Failure ( POCUSHF )","Use of Point-of-Care Ultrasound (POCUS) to Guide Fluid Management and Reduce Hospital Length of Stay in Patients With Decompensated Heart Failure","POCUSHF","Inclusion Criteria:\n\nAdults aged 18 years and older.\n\nHospitalized with a primary diagnosis of decompensated heart failure (left, right, or biventricular).\n\nEvidence of volume overload or congestion based on Framingham criteria, clinical examination, elevated proBNP (\\>1000 pg\u002FmL), or chest X-ray showing pulmonary edema.\n\nAbility to undergo bedside ultrasound evaluation (POCUS) as clinically feasible.\n\nAble to provide informed consent.\n\nExclusion Criteria:\n\nAge under 18 years.\n\nPregnant or breastfeeding women.\n\nTerminal illness with life expectancy \\\u003C 30 days.\n\nInability to obtain ultrasound images due to body habitus or other technical reasons.\n\nEnrollment in another interventional clinical trial that could interfere with the outcomes of this study.",{"count":321,"type":21},[24],"This study will evaluate whether using bedside ultrasound (also called Point-of-Care Ultrasound or POCUS) can help improve the care of hospitalized patients with decompensated heart failure. Patients will be randomly assigned to two groups: one group will receive ultrasound-guided assessments, and the other group will receive standard clinical evaluations. Researchers will compare the hospital length of stay between the two groups. Ultrasound is a non-invasive, safe, and painless imaging tool. The goal of the study is to find out if ultrasound guidance can lead to shorter hospitalizations and better care for patients with heart failure.",[348,349,350],"Heart Failure","Decompensated Heart Failure","Hospital Length of Stay",[348,349,352,353,350,354,355,356,357,358],"Point-of-Care Ultrasound","POCUS","Ultrasound-Guided Therapy","Lung Ultrasound","Inferior Vena Cava Ultrasound","Volume Status Assessment","Readmission Prevention","2026-01-13",{"date":361,"type":34},"2026-01-14",{"date":363,"type":34},"2025-11-24",{"date":334,"type":21},{"name":40,"class":41},{"id":367,"slug":368,"hasResults":11,"nctId":369,"briefTitle":370,"officialTitle":371,"acronym":4,"eligibilityCriteria":372,"healthyVolunteers":15,"sex":16,"minAge":373,"maxAge":374,"enrollmentInfo":375,"targetDuration":4,"studyType":22,"phases":376,"briefSummary":377,"conditions":378,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":359,"lastUpdatePostDateStruct":380,"startDateStruct":381,"completionDateStruct":383,"leadSponsor":385,"locationsCount":42},"100422977","chronic-widespread-pain-in-hiv-novel-mechanisms-and-therapeutics-100422977","NCT04787848","Chronic Widespread Pain in HIV: Novel Mechanisms and Therapeutics","Role of Endogenous Opioid Peptides in HIV-associated Chronic Widespread Pain","Inclusion Criteria:\n\n* Confirmed HIV diagnosis and currently a patient in the UAB 1917 HIV Clinic\n* Age 19 - 65; the lower end of this age range was chosen to capture young adults with HIV infection, and participants over 65 years are increasingly likely to meet one or more exclusion criteria\n* All people living with HIV must be currently receiving stable antiretroviral therapy (ART) for inclusion in this study\n* Non-HIV participants must be confirmed as HIV negative. HIV-negative participants with chronic widespread pain must self-report bodily pain more than once per week for at least three consecutive months and HIV-negative participants without chronic pain must self-report no pain, or pain less frequently than once per week for at least three consecutive months\n\nExclusion Criteria:\n\n* Anemia\n* Current or past history of blood disorders which may increase hemolysis\n* Active microbial infections which may alter the quantity or quality of blood inflammatory cells such as monocytes and neutrophils\n* Use of certain medication other than antiretroviral therapy that might conflict with study observations. However, participants will not be excluded or asked to withdraw from medications used for pain management since temporary withdrawal from these medications could affect pain measures (exceptions will be therapies such as methadone or buprenorphine used to treat opioid addiction). Only those who are stable on these medications for at least 60 days will be included. All patient medications used for at least the 60 days prior to participation will be recorded and controlled in statistical analyses as needed\n* Systemic rheumatic disease (e.g., rheumatoid arthritis, systemic lupus erythematosus). These rheumatologic conditions will be excluded due to their autoimmune characteristic. . Cachexia (wasting syndrome) and severe frailty. This exclusion is in place to protect against the stress of experimental pain testing\n* A history of clinically significant surgery in the past year\n* Uncontrolled hypertension (i.e. SBP\u002FDBP of \\>150\u002F95) or cardiovascular or peripheral arterial disease. These exclusions are in place primarily for safety reasons because the cold pressor task represents a cardiovascular challenge. However, uncontrolled hypertension can also affect pain perception, which is another reason for excluding these individuals\n* Poorly controlled diabetes (HbA1c \\> 8%) for both safety reasons, and because diabetic neuropathy could alter pain perception\n* Neurological disease (e.g. Parkinson's, multiple sclerosis, epilepsy)\n* Serious psychiatric disorder requiring hospitalization within the past 12 months or characterized by active suicidal ideation\n* Any participant deemed to be actively suicidal upon study screening will be escorted to the UAB emergency room and evaluated by the Psychiatry Service\n* Diminished cognitive function that would interfere with understanding of study procedures. The Realm Health Literacy Test will be administered to ensure that participants are free of cognitive impairment that would compromise study participation\n* Pregnancy. Inclusion\u002Fexclusion criteria will be verified using the screening tool in combination with review of participants' medical records","19 Years","65 Years",{"count":158,"type":21},[24],"To determine if decreased production or release of endogenous opioid peptides by peripheral immune cells contributes to hypersensitivity in people with HIV",[379],"Chronic Widespread Pain",{"date":361,"type":34},{"date":382,"type":34},"2021-11-15",{"date":384,"type":21},"2026-07-30",{"name":40,"class":41},{"id":387,"slug":388,"hasResults":11,"nctId":389,"briefTitle":390,"officialTitle":391,"acronym":4,"eligibilityCriteria":392,"healthyVolunteers":15,"sex":16,"minAge":79,"maxAge":393,"enrollmentInfo":394,"targetDuration":4,"studyType":22,"phases":396,"briefSummary":397,"conditions":398,"keywords":400,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":406,"lastUpdatePostDateStruct":407,"startDateStruct":409,"completionDateStruct":411,"leadSponsor":413,"locationsCount":42},"100609956","evaluating-a-mat-based-biometric-vibration-system-for-sleep-and-daily-recovery-100609956","NCT07221318","Evaluating a Mat-Based Biometric Vibration System for Sleep and Daily Recovery","Evaluating the Physiological and Psychological Impact of Low-Frequency Vibration Therapy: A Longitudinal Randomized Clinical Trial","Inclusion Criteria:\n\n* Adults 18-45 years.\n* Able to provide written informed consent.\n* Apparently healthy and free of unstable cardiovascular, neurological, or psychiatric conditions per screening.\n* Cleared for low-to-moderate intensity whole-body vibration delivered supine\u002Frecumbent on a mat.\n* Willing and able to comply with study procedures: two lab visits; 3-week home protocol (3-4 days\u002Fweek); three 15-min sessions; brief affect check-ins and daily logs.\n* Willing to abstain from caffeine, alcohol, and strenuous exercise for 24 hours before each lab visit and to attend visits at the same time of day.\n* Able to lie supine for 15 minutes and follow instructions for the HRV device.\n\nExclusion Criteria:\n\n* Implanted electronic medical devices (e.g., pacemaker, neurostimulator).\n* Uncontrolled hypertension or severe vestibular disorders.\n* Current substance dependence.\n* Medications known to markedly affect autonomic function or sleep architecture (e.g., beta-blockers, antiarrhythmics, sedative-hypnotics, antidepressants with strong autonomic effects).\n* Diagnosed neurological or psychological disorders that substantially affect emotional processing or autonomic regulation (severe psychiatric conditions).\n* Prior extensive experience with vibration therapies (to minimize expectancy bias).\n* Any condition judged by study staff to contraindicate vibration exposure or preclude safe participation (including inability to tolerate supine\u002Frecumbent position).\n* Unwillingness to refrain from initiating new structured exercise or relaxation programs during the study period.","45 Years",{"count":395,"type":21},50,[24],"The goal of this randomized clinical trial is to learn whether a low-frequency \"kinetic wellness\" mat (a comfortable mat that gently vibrates) can improve stress recovery, sleep quality, mood, and attention in healthy adults ages 18-45.\n\nThe main questions it aims to answer are:\n\n* After 3 weeks, does regular use of the vibrating mat increase heart rate variability (a noninvasive marker of the body's ability to recover from stress) and improve sleep, mood, perceived stress, and anxiety compared with no mat use?\n* Do patterns of resting brain activity (measured with EEG) and heart rate variability (HRV) change from before to after the program, and are those changes related to each other?\n\nResearchers will compare two groups: an Experimental group that uses the vibrating mat at home for 3 weeks, and a Control group that does not use the mat. Participants are randomly assigned to a group.\n\nParticipants will:\n\n* Attend two lab visits (\\~60 min) for questionnaires, resting heart activity (HRV) and brain activity (EEG), and a brief attention test.\n* On 3-4 days per week for 3 weeks:\n* Experimental group: use the vibrating mat for 15 minutes while recording HRV.\n* Control group: lie quietly for 15 minutes while recording HRV.\n* Both groups: record HRV for 15 minutes before bedtime and 15 minutes after waking on those same days.\n* Both groups: complete quick check-ins on feelings (after sessions and the next morning) and log caffeine\u002Falcohol, exercise, and medications.",[399],"Healthy Adult Male and Female Volunteers",[401,402,403,404,405],"whole-body vibration therapy","sleep quality","affect","mood","relaxation therapy","2025-10-24",{"date":408,"type":34},"2025-10-27",{"date":410,"type":34},"2025-10-06",{"date":412,"type":21},"2026-05",{"name":40,"class":41},{"id":415,"slug":416,"hasResults":11,"nctId":417,"briefTitle":418,"officialTitle":418,"acronym":4,"eligibilityCriteria":419,"healthyVolunteers":11,"sex":16,"minAge":373,"maxAge":420,"enrollmentInfo":421,"targetDuration":4,"studyType":22,"phases":422,"briefSummary":423,"conditions":424,"keywords":427,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":430,"lastUpdatePostDateStruct":431,"startDateStruct":433,"completionDateStruct":435,"leadSponsor":437,"locationsCount":42},"100608269","uncovering-the-mechanism-of-pain-relief-by-peripheral-transcutaneous-magnetic-stimulation-100608269","NCT07199361","Uncovering the Mechanism of Pain Relief by Peripheral Transcutaneous Magnetic Stimulation","Inclusion Criteria:\n\n* Confirmed diagnosis of chronic peripheral pain secondary to trauma or surgery. Age 19 - 80; the lower end of this age range was chosen to capture young adults with pain, and participants over 80 years are increasingly likely to meet one or more exclusion criteria.\n\nCurrently receiving pain medication Chronic pain must self-report peripheral pain, more than once per week, for at least three consecutive months\n\nExclusion Criteria:\n\n* Implanted Electronic Devices and \u002F or Conductive Objects in or near the head: Patients who have an implanted device that is activated or controlled in any way by physiological signals (examples: deep brain stimulators, cochlear implants, and vagus nerve stimulators).\n\nNon-Removable Metallic Objects near the coil: Patients who have conductive, ferromagnetic, or other magnetic-sensitive metals implanted in their head or within 30 cm of the treatment coil (examples: cochlear implants, implanted electrodes\u002Fstimulators, aneurysm clips or coils, stents, and bullet fragments). F NOTE: Standard amalgam dental fillings are not affected by the magnetic field and are acceptable in patients.\n\nActive microbial infections may alter the quantity or quality of blood inflammatory cells such as monocytes and neutrophils.\n\nPositive Urine Drug test: (COC\u002FAMP\u002FOPI\u002FmAMP\u002FPCP\u002FBAR\u002FBZO\u002FMTD\u002FMDMA\u002FOXY\u002FPPX\u002FBUP\u002FTCA) Use of any medication other than pain medications. However, participants will not be excluded or asked to withdraw from medications used for pain management since temporary withdrawal from these medications could affect pain measures (exceptions will be therapies such as methadone or buprenorphine used to treat opioid addiction). Only those who have been stable on these medications for at least 60 days will be included. All patient medications used for at least 60 days prior to participation will be recorded and controlled in statistical analyses as needed.\n\nSystemic rheumatic disease (e.g., rheumatoid arthritis, systemic lupus erythematosus). These rheumatologic conditions will be excluded due to their autoimmune characteristic.\n\nCachexia (wasting syndrome) and severe frailty as determined by the Groningen Frailty Index (score \\>4). This exclusion is in place to protect against the stress of experimental pain testing.\n\nUncontrolled hypertension (i.e. SBP\u002FDBP of \\>140\u002F90) or cardiovascular or peripheral arterial disease. These exclusions are in place primarily for safety reasons because the cold pressor task represents a cardiovascular challenge. However, uncontrolled hypertension can also affect pain perception, which is another reason for excluding these individuals.\n\nPoorly controlled diabetes (HbA1c \\> 8%) for both safety reasons and because diabetic neuropathy could alter pain perception.\n\nNeurological disease (e.g. Parkinson's, multiple sclerosis). Serious psychiatric disorder requiring hospitalization within the past 12 months or characterized by active suicidal ideation. Any participant deemed to be actively suicidal upon study screening will be escorted to the emergency room and evaluated by the Psychiatry Service.\n\nA diminished cognitive function that would interfere with the understanding of study procedures. The Mini-Mental Status Exam (MMSE) will be administered to ensure that participants are free of cognitive impairment that would compromise study participation. MMSE \\\u003C18 will be excluded.\n\nPregnancy","80 Years",{"count":395,"type":21},[24],"This research aims to uncover the Mechanisms of pain relief through the FDA-cleared peripheral transcutaneous magnetic stimulation (pTMS) device by MagVenture. 50 people with chronic pain (post-surgical or post-traumatic) will be identified and recruited. The eligibility for participation in the study will be evaluated by a series of pain and mental health questionnaires followed by quantitative sensory testing (QST) to assess response to noxious heat, cold, and pressure stimuli. Blood will be drawn to isolate plasma, serum, and leukocytes. Participants will then undergo pTMS at the site of pain for four consecutive days. At the end of the therapy, pain testing will be done again, followed by blood withdrawal to assess the changes in plasma and leukocyte levels of mediators of pain. It is anticipated that pTMS will increase mediators of pain relief and reduce inflammatory mediators. Risks: It is possible that a few participants may not respond to pTMS therapy. However, plasma analysis of mediators of pain may help stratify these participants into responders vs. non-responders. Risks associated with the study are minimal and mainly involve discomfort associated with pain testing. The importance of knowledge gained includes understanding pain relief mechanisms by medical devices such as pTMS, which will result in better pain management.",[425,426],"Post-Surgical Pain, Chronic","Post-traumatic Pain, Chronic",[428,429],"Peripheral Transcutaneous Magnetic Stimulation","Post-Traumatic and Post-Surgical Chronic Pain","2025-09-26",{"date":432,"type":34},"2025-09-30",{"date":434,"type":34},"2025-03-24",{"date":436,"type":21},"2028-02-25",{"name":40,"class":41},{"id":439,"slug":440,"hasResults":11,"nctId":441,"briefTitle":442,"officialTitle":443,"acronym":4,"eligibilityCriteria":444,"healthyVolunteers":11,"sex":16,"minAge":445,"maxAge":446,"enrollmentInfo":447,"targetDuration":4,"studyType":22,"phases":449,"briefSummary":450,"conditions":451,"keywords":454,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":459,"lastUpdatePostDateStruct":460,"startDateStruct":462,"completionDateStruct":464,"leadSponsor":466,"locationsCount":42},"100561166","a-remotely-delivered-tai-chiqigong-intervention-for-older-people-living-with-hiv-100561166","NCT06586619","A Remotely Delivered Tai Chi\u002FQigong Intervention for Older People Living With HIV","A Remotely Delivered Tai Chi\u002FQigong Intervention for Older People Living With HIV: A Randomized Clinical Trial","Inclusion Criteria:\n\nIn order to be eligible to participate in this study, an individual must meet all of the following criteria:\n\n1. The ability to provide consent assessed by the GAIN Cognitive Impairment Scale\n2. Provision of signed and dated informed consent form\n3. Must be 50 - 75 years old.\n4. Must have been diagnosed with HIV by a healthcare professional (status confirmed at baseline by an uploaded picture of a recent lab report or medication bottle with name),\n5. Must have reliable internet access,\n6. Must have a smart phone\n7. No substantial experience (regular weekly practice for more than 3 months in the past 12 months) with mind-body interventions,\n8. Willing to participate for the length of the 12-week intervention and follow up assessments (a total of 12 months).\n9. Must report stable housing for the past 60 days and the next 60 days;\n10. Must have mild to moderate depressive symptoms (a score more than 5 but less than 19 on the PHQ-9 scale)\n11. Must speak and understand English\n\nExclusion Criteria:\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n1. Reports high risk for suicide based on the CCSR screening tool.\n2. Has participated in a study on mental health in the last 12 months.\n3. Currently exercising at least 150 minutes a week","50 Years","75 Years",{"count":448,"type":21},326,[24],"The goal of this randomized clinical trial is to learn if tai chi\u002Fqigong decreases depressive symptoms among older people living with HIV compared to a health education class. The main questions it aims to answer are:\n\nDoes tai chi\u002Fqigong reduce depressive symptoms among older people living with HIV more than a health education class? What are the behavioral, psychological, and biological mechanisms in which tai chi\u002Fqigong affects depressive symptoms? Does tai chi\u002Fqigong affect depressive symptoms among older people living with HIV differently for men compared to women?\n\nResearchers will compare a 12-week, twice a week remotely delivered tai chi\u002Fqigong intervention to a health education class of the same duration to determine if it improves depressive symptoms among older people living with HIV.\n\nParticipants will:\n\nAttend either a tai chi\u002Fqigong class twice a week for 12 weeks or a health education class of the same duration delivered via Zoom. Each class will be 45-60 minutes in length.\n\nParticipate in 3 separate interviewer-administered interviews: at the time of enrollment, 3 months after the last class, and 9 months after the last class.\n\nKeep a tracking log of their home practice of tai chi\u002Fqigong (only participants in the intervention group).\n\nUse a biosensor (an earlobe sensor or chest strap) to measure their heart variability.\n\nGo to their local lab (e.g., Quest or Labcorp) for blood draw at the time of enrollment and at 9 month post intervention (this will only be a subset of participants).",[452,453],"Depressive Symptoms","Hiv",[266,85,455,456,457,458],"older","tai chi","mindfulness","intervention","2025-08-30",{"date":461,"type":34},"2025-09-08",{"date":463,"type":34},"2025-08-04",{"date":465,"type":21},"2029-05",{"name":40,"class":41},{"id":468,"slug":469,"hasResults":11,"nctId":470,"briefTitle":471,"officialTitle":471,"acronym":4,"eligibilityCriteria":472,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":473,"targetDuration":4,"studyType":22,"phases":475,"briefSummary":476,"conditions":477,"keywords":479,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":463,"lastUpdatePostDateStruct":483,"startDateStruct":485,"completionDateStruct":487,"leadSponsor":488,"locationsCount":42},"100509865","interventions-for-english-language-learners-at-risk-for-adhd-100509865","NCT05918991","Interventions for English Language Learners At-Risk for ADHD","Inclusion Criteria:\n\n* Identified as an English Language Learner Level 1 through 4 by their school district\n* Enrolled in kindergarten or 1st grade during the year of participation\n* 6 or more symptoms of attention-deficit\u002Fhyperactivity disorder endorsed by parent or teacher\n* Has a teacher who is willing to participate\n* Has a parent or primary caregiver who is willing to participate\n\nExclusion Criteria:\n\n* Participant has an active Individualized Education Plan for language or behavior\n* Participant IQ is less than 70\n* Participant is diagnosed with psychosis\n* Participant is diagnosed with autism spectrum disorder with severity level 2 or greater or another pervasive developmental disorder\n* Participant is enrolled in home-school",{"count":474,"type":21},300,[24],"The goal of this clinical trial is to compare the effect of language and behavioral interventions for students who are English language learners and who have symptoms of attention-deficit\u002Fhyperactivity disorder (ADHD). The main question it aims to answer is:\n\n\\- Which intervention is better for the students: the behavioral intervention, the language intervention, or a combination of the behavioral and language interventions?\n\nParticipants will be asked to do the following:\n\n* Participants' parents and teachers will be asked to complete questionnaires about their behavior.\n* Participants will be asked to complete tests assessing language, cognitive, and academic abilities.\n* Members of the research team will complete classroom observations for the participating students.\n* Participants will be randomly assigned to one of four groups: a school as usual group, a language group, a daily report card group, and a combined daily report card and language group.\n\n  * If assigned to the language group, participants will receive an 18-week language intervention.\n  * If assigned to the daily report card group, a behavioral consultant will work with participants' parents and teachers to set up a home-school behavior plan called a daily report card.\n  * If assigned to the combined daily report card and language group, participants will receive both the language intervention and the daily report card.\n  * If assigned to the school as usual group, participants will no study interventions.\n\nResearchers will compare the language group, the daily report card group, the combined language and daily report card group, and the school as usual group to see which group has the best language learning and classroom behavior at the end of the program.",[478],"Attention Deficit Hyperactivity Disorder",[480,481,482],"English Language Learners","Classroom Behavioral Intervention","Language Intervention",{"date":484,"type":34},"2025-08-07",{"date":486,"type":34},"2022-05-18",{"date":384,"type":21},{"name":40,"class":41},{"id":490,"slug":491,"hasResults":11,"nctId":492,"briefTitle":493,"officialTitle":494,"acronym":4,"eligibilityCriteria":495,"healthyVolunteers":11,"sex":16,"minAge":496,"maxAge":17,"enrollmentInfo":497,"targetDuration":4,"studyType":22,"phases":499,"briefSummary":501,"conditions":502,"keywords":521,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":526,"lastUpdatePostDateStruct":527,"startDateStruct":529,"completionDateStruct":531,"leadSponsor":533,"locationsCount":42},"100505178","phase-1-ex-vivo-drug-sensitivity-testing-and-multi-omics-profiling-100505178","NCT05857969","Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling","Adopting a Functional Precision Medicine Approach For Individualized Pediatric Cancer Treatments","Inclusion Criteria:\n\n* Patients aged 21 years or younger at the time of enrollment on this study of any gender, race or ethnicity.\n\nSubjects with suspected or confirmed diagnosis of recurrent or refractory cancer Subjects who are scheduled for or have recently had biopsy or tumor excised (solid tumors) or bone marrow aspirate (blood cancers) Subjects willing to have a blood draw or buccal swab done for the purposes of genetic testing Subjects or their parents or legal guardians willing to sign informed consent Subjects aged 7 to 17 willing to sign assent\n\nExclusion Criteria:\n\n* Subjects who do not have malignant tissue available and accessible The amount of excised malignant tissue is not sufficient for the ex vivo drug testing and\u002For genetic profiling.\n\nPatients with newly diagnosed tumors and tumors that have high (\\>90%) cure rate with safe standard therapy.","1 Day",{"count":498,"type":21},65,[500],"PHASE1","Functional precision medicine (FPM) is a relatively new approach to cancer therapy based on direct exposure of patient- isolated tumor cells to clinically approved drugs and integrates ex vivo drug sensitivity testing (DST) and genomic profiling to determine the optimal individualized therapy for cancer patients. In this study, we will enroll relapsed or refractory pediatric cancer patients with tissue available for DST and genomic profiling from the South Florida area, which is 69% Hispanic and 18% Black. Tumor cells collected from tissue taken during routine biopsy or surgery will be tested.",[503,504,505,506,507,508,509,510,511,512,513,514,515,516,517,518,519,520],"Recurrent Childhood Acute Myeloid Leukemia","Recurrent Childhood Acute Lymphoblastic Leukemia","Recurrent Childhood Large Cell Lymphoma","Refractory Childhood Acute Lymphoblastic Leukemia","Refractory Childhood Hodgkin Lymphoma","Refractory Childhood Malignant Germ Cell Neoplasm","Recurrent Childhood Brain Tumor","Recurrent Childhood Brainstem Glioma","Recurrent Childhood Rhabdomyosarcoma","Recurrent Childhood Soft Tissue Sarcoma","Recurrent Childhood Ependymoma","Recurrent Childhood Lymphoblastic Lymphoma","Recurrent Childhood Gliosarcoma","Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive","Refractory Childhood Malignant Solid Neoplasm","Recurrent Childhood Malignant Solid Neoplasm","Recurrent Childhood Malignant Neoplasm","Refractory Childhood Malignant Neoplasm",[522,523,524,525],"ex vivo drug sensitivity assay","genomic profiling","Functional precision medicine","Biomarker development","2025-07-08",{"date":528,"type":34},"2025-07-11",{"date":530,"type":34},"2023-02-22",{"date":532,"type":21},"2028-12-31",{"name":40,"class":41},""]